Akari Therapeutics, Plc (AKTX)
Automate Your Wheel Strategy on AKTX
With Tiblio's Option Bot, you can configure your own wheel strategy including AKTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AKTX
- Rev/Share 0.0
- Book/Share 0.0004
- PB 1.6944
- Debt/Equity 0.0849
- CurrentRatio 0.1602
- ROIC -0.6013
- MktCap 21719.0
- FreeCF/Share -0.0002
- PFCF -0.002
- PE -2.0551
- Debt/Assets 0.0362
- DivYield 0
- ROE -2.1359
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology
Published: May 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical product candidates Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical product candidates
Read More
Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON and LONDON, May 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and CEO of Akari, will present and discuss recent corporate events at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Thursday, May 29, 2025 at 2:00 PM ET.
Read More
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15.
Read More
Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products
Read More
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and hematological malignancies that have total annual sales of $1B
Read More
Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
On-demand video webcast now available here BOSTON and LONDON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADC) for the treatment of cancer, today announced it participated in the Virtual Investor “Top 5 for ‘25” On-Demand Conference. As part of the event, Dr. Samir Patel, President and Chief Executive Officer of Akari Therapeutics, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to Akari in 2025.
Read More
About Akari Therapeutics, Plc (AKTX)
- IPO Date 2014-01-06
- Website https://www.akaritx.com
- Industry Biotechnology
- CEO Mr. Abizer Gaslightwala
- Employees 8